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RESEARCH ARTICLE Open Access
Are depression and anxiety associated with
disease activity in rheumatoid arthritis? A
prospective study
Faith Matcham1*, Sheila Ali2, Katherine Irving3, Matthew Hotopf1 and Trudie Chalder1,2
Abstract
Background: This study aimed to investigate the impact of depression and anxiety scores on disease activity at
1-year follow-up in people with Rheumatoid Arthritis (RA).
Methods: The Hospital Anxiety Depression Scale (HADS) was used to measure depression and anxiety in a cross-
section of RA patients. The primary outcome of interest was disease activity (DAS28), measured one-year after baseline
assessment. Secondary outcomes were: tender joint count, swollen joint count, erythrocyte sedimentation rate and
patient global assessment, also measured one-year after baseline assessment. We also examined the impact of baseline
depression and anxiety on odds of reaching clinical remission at 1-year follow-up.
Results: In total, 56 RA patients were eligible for inclusion in this analysis. Before adjusting for key demographic and
disease variables, increased baseline depression and anxiety were associated with increased disease activity at one-year
follow-up, although this was not sustained after adjusting for baseline disease activity. There was a strong association
between depression and anxiety and the subjective components of the DAS28 at 12-month follow-up: tender joint
count and patient global assessment. After adjusting for age, gender, disease duration and baseline tender joint count
and patient global assessment respectively, higher levels of depression and anxiety at baseline were associated with
increased tender joint count and patient global assessment scores at 1-year follow-up.
Conclusions: Symptoms of depression and anxiety have implications for disease activity, as measured via the DAS28,
primarily due to their influence on tender joints and patient global assessment. These findings have implications for
treatment decision-making as inflated DAS28 despite well controlled inflammatory disease markers may indicate
significant psychological morbidity and related non-inflammatory pain, rather than true disease activity.
Keywords: Depression, Anxiety, Rheumatoid arthritis, Prospective, Disease activity
Background
Rheumatoid Arthritis (RA) is a chronic autoimmune dis-
ease, with a worldwide adult prevalence of 0.2–1.2 % [1].
The disease is painful and progressive, leading to in-
creasing levels of disability and systemic complications
[2]. There is currently no cure for RA: treatment aims
are to reduce pain and inflammation, delay joint erosion
and maintain function [3]. Depression and anxiety are
highly prevalent in rheumatoid arthritis (RA). According
to a recent meta-analysis [4], 14.8 % of patients screen
positive for depression when measured with the Hospital
Anxiety and Depression Scale (HADS [5]) with a thresh-
old of 11 or more indicating the presence of depression.
This prevalence estimate is substantially higher than the
5.0 % level reported in the general population [6]. Symp-
toms of anxiety are also frequently reported in RA, with
25.1 % of RA outpatients screening positive for anxiety
according to the 7-item Generalised Anxiety Disorder
(GAD-7 [7]) questionnaire [8]. Anxiety and depression
are sometimes grouped together and referred to as
“common mental disorders”. Anxiety and depression
may also be seen as symptoms which are present with
varying degrees of severity in the population. In this
paper, we refer to depression and anxiety scores as
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continuous indicators of symptom severity, rather than
as disorders reaching a threshold of severity. This
method is particularly beneficial as it maximises statis-
tical power, and allows examination of the linear associa-
tions between mental health and disease outcomes [9,
10].
RA has significant implications for patient quality-of-
life [11] and increased psychological symptoms in RA is
associated with poorer patient outcomes including in-
creased pain [12], fatigue [13], service usage [14] and
increased risk of premature mortality [15]. The relation-
ship between mental and physical health is bidirectional.
Experiencing psychological distress may inflate the sub-
jective severity of patient-reported symptoms such as
pain and tenderness [16]. Additionally, psychological dis-
tress may impact health outcomes by influencing health
behaviours such as medication adherence [17] and
smoking [18]. Reduced levels of physical activity can re-
sult in de-conditioning, loss of natural endorphins and
increased pain [19]. Furthermore, common mental disor-
ders are associated with immune dysregulation [20–22].
A recent systematic review has found that only seven
studies have examined the longitudinal relationships be-
tween depression and RA outcomes [23]. This review
concluded that depression may worsen pain and disease
activity, and reduce treatment efficacy, although evi-
dence is limited by a small number of studies, often of
poor quality. Studies frequently lacked a priori hypoth-
eses, used convenience samples, and had inadequate ad-
justment for confounders [23]. We previously reported
that increased psychological distress predicts increased
disease activity (measured via the 28-joint Disease Activ-
ity Score; DAS28 [24]) and reduced odds of reaching
clinical remission over a 2-year follow-up period, how-
ever this research is limited by its sub-standard identifi-
cation of psychological distress, and its use of clinical
trial data representing a relatively homogenous group of
patients [25].
More research is needed to resolve these issues and
replicate previous research findings, using robust
methods of identifying depression and anxiety in a nat-
uralistic patient sample. This could have substantial im-
plications for the treatment of RA: if depression and
anxiety are drivers of the non-inflammatory components
of DAS28 disease activity, optimal RA treatment plans
could involve the pharmacological or psychological man-
agement of depression and anxiety alongside RA. We
therefore aimed to explore the relationship between de-
pression and anxiety and disease activity after one year.
We tested three hypotheses: 1) that increased depression
and anxiety symptom severity at baseline would be sig-
nificantly associated with increased DAS28 at 1-year
follow-up; 2) that the relationship between depression
and anxiety and DAS28 would be primarily driven by an
association between depression and anxiety and the sub-
jective DAS28 components: tender joint count (TJC)
and patient global assessment (PGA); and 3) that in-
creased levels of depression and anxiety at baseline
would be associated with reduced odds of reaching clin-
ical remission at 1-year follow-up.
Methods
Procedure and participants
This was a one-year prospective study, aiming to exam-
ine the psychological factors associated with disease out-
comes in RA. Patients attending a rheumatology
outpatient appointment at King’s College Hospital,
London, were approached consecutively in the clinic
waiting room and invited to participate. All patients
were approached and consenting patients completed the
questionnaires regardless of diagnosis. RA diagnosis was
confirmed through checking their hospital records, to
verify clinician-diagnosed RA. Only data from patients
with RA diagnosis according to 2010 ACR/EULAR cri-
teria [26] were included in the current analysis. Figure 1
shows the flow of participants through the recruitment
and analysis strategy. The following inclusion criteria
were required for the subsample described in this study:
clinician confirmed RA diagnosis; aged 18 years or over;
attending the hospital outpatient clinic. Patients were
excluded if they had insufficient English to be able to
read and understand the questionnaires.
Participants gave informed consent and were asked to
complete a baseline questionnaire, which was completed
during their hospital visit. Outcome data were obtained
from patient medical records from appointments at 1-
year (±3 months) after the baseline questionnaire was
completed.
The study protocol was approved by the South East
London Research Ethics Committee (REC reference
number: 10/H0808/135).
Data collection
Baseline/predictor variables
Baseline depression and anxiety were measured via the
questionnaire administered in the hospital waiting room.
The questionnaire packs included several measures of
psychological, social, disease and work-related variables,
however only responses to the HADS were included in
the current study. The HADS consists of 14 items, 7 for
symptoms of depression and 7 for anxiety symptoms.
Each item has 4 possible interval response options¸ pro-
viding a score from 0–3 and the summed total gives a
score out of 21 for each subscale, with higher scores in-
dicating higher levels of depression or anxiety. The
HADS depression and anxiety subscales have good dis-
criminant validity when compared to psychiatric assess-
ment [5], are internally consistent (α = 0.85 and 0.78
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respectively), and have good convergent validity in RA
patients [9, 10].
Follow-up/outcome variables
The primary outcome to test hypothesis 1 was DAS28.
The DAS28 is considered to be the gold-standard indica-
tor of disease activity: it is recommended by all major
RA guidelines; is widely used both in clinical trials and
as part of clinical practice; and takes into account sub-
jective and objective indicators of disease severity [27].
Its subcomponents TJC, SJC, PGA and ESR were used
as secondary outcomes, examining the impact of depres-
sion and anxiety on the subjective (TJC, PGA) and ob-
jective components (SJC, ESR) of disease activity
(hypothesis 2). PGA is measured on a visual analogue
scale, providing a patient perspective on their health sta-
tus; scores range between 0 (worst health) and 100 (best
health). Due to the composite nature of the DAS28, total
scores can be inflated by non-inflammatory pain, dem-
onstrated in high levels of PGA and TJC, despite well-
managed inflammation [28]. We hope to investigate this
by examining the overall DAS28 alongside individual as-
sessment of its subcomponents.
To examine the impact of depression and anxiety on
odds of reaching clinical remission after 1 year (hypoth-
esis 3), the number of patients scoring <2.6 on the
DAS28 at 1-year follow-up was established [29].
Only data from one follow-up appointment were in-
cluded, with all disease outcomes identified from hos-
pital records to match as closely as possible to 1 year
post-baseline, with a ± 3-month window of acceptability.
Statistical analysis
Missing data
Of the 56 eligible participants, one patient had missing
baseline HADS data, and one had missing baseline
DAS28 data. Six patients had missing DAS28 scores at
follow-up: two did not attend a follow-up appointment
within the given ± 3 month time-frame and four did not
have their DAS28 measured within the ± 3 month time-
frame.
Patients with missing outcome data did not significantly
differ from patients without missing data in relation to
their age, gender, baseline disease activity, ESR, TJC, PGA,
SJC, depression, or anxiety (further details available on ap-
plication from the author). This assessment revealed no
systematic differences between participants with and with-
out missing data and missing data were managed via mul-
tiple imputation. In addition to outcome data, baseline
data, demographics and all covariates were used to impute
the missing values, using chained equations with 13 cycles.
The 13 datasets were separately analysed and combined
using Rubin’s rules [30].
Fig. 1 Flowchart of participant recruitment
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Hypothesis testing
ESR found to be non-normal in distribution and was
log transformed prior to analysis. No other parametric
assumptions were violated and therefore multiple lin-
ear regression models were created to test hypotheses
1 and 2. These models were created using Stata (ver-
sion 11.2), providing unstandardised b coefficients,
standard errors (SE), 95 % confidence intervals (CI)
and p-values. Unadjusted and adjusted models were
created. Adjustment included: disease duration, age,
and baseline score of each outcome variable (for
example, baseline DAS28 was adjusted for in the
model predicting follow-up DAS28; baseline TJC was
adjusted for in the model predicting follow-up TJC).
Age was adjusted for due to the large age-range
represented in the sample (26–83 years). Disease
duration was selected as a covariate due to its strong
association with outcome variables, established
through preliminary bivariate correlation analyses.
Baseline scores for outcome variables were adjusted
for in order to ascertain the association between de-
pression and anxiety irrespective of baseline severity.
Table 1 Baseline demographic, disease and psychological variables
Variable N (%) M(SD) Observed range
Total N 56
Demographics
Female, N (%) 44 (78.6)
Mean age 53.6 (13.4) 26–83
Ethnicity, N (%) White 35 (64.8)
Asian 7 (13.0)
Black 11 (20.4)
Mixed 1 (1.9)
Not reported 2 (3.8)
Disease characteristics (baseline)
Mean disease duration (Years) 10.3 (9.2) 0.2–38
Experiencing comorbidity, N (%) 32 (57.1)
Treatment type, N (%) DMARD 38 (67.9)
Biologics 14 (25.0 %)
Not reported/other 4 (7.1 %)
Rheumatoid factor positive N (%) 40 (71.4)
Median ESR (IQR) 27.0 (12.0–44.0) 2–102
Mean TJC 5.2 (6.1) 0–24
Mean SJC 3.0 (2.9) 0–10
Mean PGA 45.8 (25.0) 1–90
Mean DAS-28 4.5 (2.2) 0.9–14.1
Clinical remission (DAS-28 < 2.6), N (%) 8.0 (14.6)
Psychological status (baseline)
Mean depression 7.4 (4.7) 0–20
Mean anxiety 7.7 (5.0) 0–20
Disease characteristics (follow-up)
ESR, median (IQR) 22.5 (8.0–44.0) 2–114
TJC, M (SD) 4.0 (5.8) 0–28
SJC, M (SD) 3.2 (3.8) 0–16
PGA, M (SD) 44.6 (26.1) 1–100
DAS-28, M (SD) 4.7 (2.8) 0.5–17.1
Clinical remission (DAS-28 < 2.6), N (%) 8.0 (16.0)
M mean, SD standard deviation, DMARD disease modifying anti-rheumatic drug, NSAID non-steroidal anti-inflammatory drug, ESR erythrocyte sedimentation rate,
TJC tender joint count, SJC swollen joint count, PGA patient global assessment, DAS-28 28 joint disease activity scale, HADS-D hospital anxiety and depression scale
depression subscale, HADS-A hospital anxiety and depression scale anxiety subscale
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To assess hypothesis 3, a logistic regression model was
created to examine the association between baseline de-
pression and anxiety scores and odds of reaching clinical
remission at 1-year. An unadjusted model and one ad-
justed for disease duration, age, and baseline disease ac-
tivity are presented.
Results
Participant characteristics
Figure 1 shows the flow of participants through the
study. Of the 235 patients who completed the question-
naire, 109 (46 %) had self-reported RA. Of these, only 56
(51.3 %) had clinically verified RA. Table 1 shows the de-
scriptive statistics of the 56 participants included in the
current analysis. In total, 78.6 % of participants were fe-
male, and the mean age was 53.6 years. The majority of
participants identified themselves as White (64.8 %). The
mean time between baseline and follow-up measure-
ments was 1.1 years (SD = 0.4).
Hypothesis 1: the relationship between baseline
depression and anxiety and follow-up disease activity
Table 2 shows the results of Pearson’s correlation ana-
lyses examining bivariate associations between demo-
graphics, baseline variables and DAS28 at follow-up.
Table 3 shows the results of multiple regression
models, examining the impact of baseline depression
and anxiety level on DAS28. The results of this analysis
revealed that both depression and anxiety scores at base-
line were associated with increased DAS28 at 1-year
follow-up, however this relationship became non-
significant after adjustment for covariates.
Hypothesis 2: the relationship between baseline
depression and anxiety and follow-up DAS28 components
Table 2 shows the results of Pearson’s correlation ana-
lyses examining bivariate associations between demo-
graphics, baseline variables and follow-up DAS28
components: ESR, TJC, SJC, and PGA.
Table 3 also shows the models created for the sub-
components of the DAS28: ESR, SJC, TJC and PGA.
These analyses revealed no significant associations be-
tween depression or anxiety and the more objective
components: ESR and SJC. Coefficients were small, and
did not reach a level of statistical significance. Increased
depression was found to be significantly associated with
increased follow-up TJC both before and after adjust-
ment, with a one unit increase in HADS depression at
baseline contributing to a 0.59 increase in TJC at follow-
up. However the relationship between anxiety and TJC
only reached statistical significance after adjusting for
covariates, with an increase in HADS anxiety at baseline
contributing to a 0.44 increase in TJC at follow-up.
Similarly, depression was a significant predictor of PGA
at 1-year follow-up both before and after adjustment:
after adjustment, a one unit increase in HADS depres-
sion at baseline was associated with an increase in PGA
of 2.07 units. Increasing anxiety was associated with in-
creased follow-up PGA both before and after adjusting
for covariates, with a post-adjustment increase of one
unit in baseline HADS anxiety associated with a 2.13 in-
crease in PGA at follow-up.
Hypothesis 3: the relationship between depression and
anxiety and odds of reaching clinical remission
At baseline, 8 (16.0 %) of patients were in clinical remis-
sion (DAS28 < 2.6) and 8 (16.0 %) were in remission at
follow-up. Of the 8 in remission at baseline, 6 were still
in remission at follow-up; the remaining 2 patients in re-
mission at follow-up were new cases. Table 4 shows the
results of the logistic regression model assessing the as-
sociations between depression and anxiety scores and
odds of reaching clinical remission.
Neither depression nor anxiety at baseline were signifi-
cantly associated with the odds of being in clinical re-
mission at one-year follow-up.
Discussion
We have found evidence to support one of the three hy-
potheses: 1) depression and anxiety scores at baseline
were not significant predictors of DAS28 disease activity
at 1-year follow-up after full adjustment; 2) depression
and anxiety were significantly associated with the sub-
jective components of the DAS28: TJC and PGA; 3) de-
pression and anxiety were not significantly associated
with the odds of reaching clinical remission at 1-year
follow-up after adjusting for covariates. These results
support our previous findings from clinical trial data
showing a longitudinal relationship between baseline de-
pression/anxiety and follow-up tender joints, patient glo-
bal assessment, however we failed to replicate our
previous finding of an association between depression
and anxiety and disease activity [25]. The current study
uses a more robust, validated method of identifying de-
pression and anxiety, in a more heterogeneous clinical
sample, with longer and more variable disease duration.
This strengthens the evidence indicating a prospective
relationship between depression and anxiety and poorer
subjective disease outcomes in RA [23]. Our failure to
replicate the association between depression and anxiety
and odds of reaching clinical remission may be due to a
lack of statistical power to predict a binary outcome.
There are several possible explanations for the associa-
tions found between depression and anxiety and patient
global assessment and tender joint counts. The negative
cognitions often experienced in depression and anxiety
[31] may contribute to how RA patients interpret and
perceive their symptoms [32]. Psychological distress is
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Table 2 Pearson correlational relationships between continuous demographic, baseline and follow-up variables
Demographics Baseline variables Follow-up variables
Age Disease duration N. comorbidities ESR TJC SJC PGA DAS-28 Depression Anxiety ESR TJC SJC PGA DAS-28
Age -
Disease duration 0.29* -
Number of comorbidities 0.32 0.22 -
Baseline Variables ESR 0.10 0.27* 0.07 -
TJC −0.13 0.07 0.13 −0.13 -
SJC −0.14 −0.03 0.03 0.11 0.54** -
PGA −0.20 0.16 0.25 0.18 0.64*** 0.45*** -
DAS-28 −0.17 0.13 0.03 0.44*** 0.41** 0.47*** 0.60*** -
Depression −0.26 0.12 −0.16 0.04 0.25 0.23 0.44** 0.40** -
Anxiety −0.29* −0.02 −0.11 0.03 0.16 0.19 0.31* 0.29* 0.76*** -
Follow-up Variables ESR 0.10 0.33* −0.01 0.86*** −0.13 −0.02 0.16 0.37** 0.03 0.03 -
TJC 0.18 0.23 0.15 −0.18 0.24 0.00 0.32* 0.07 0.34* 0.23 0.02 -
SJC 0.33* 0.32* 0.16 0.23 0.01 0.01 0.11 0.07 0.16 0.08 0.44** 0.64*** -
PGA 0.19 0.33* 0.03 0.11 0.29* 0.19 0.46*** 0.45*** 0.45*** 0.43** 0.22 0.37** 0.23** -
DAS-28 −0.03 0.21 0.06 0.36** 0.07 0.08 0.35* 0.80*** 0.39** 0.33* 0.47** 0.33* 0.36* 0.61*** -
ESR erythrocyte sedimentation rate, TJC tender joint count, SJC swollen joint count, PGA patient global assessment, DAS-28 28 joint disease activity scale, HADS-D hospital anxiety and depression scale depression
subscale, HADS-A hospital anxiety and depression scale anxiety subscale. * p < 0.05, **p < 0.01, ***p < 0.001
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associated with worsened health behaviours such as fail-
ure to take medications as prescribed [17], and increased
smoking [18], or may contribute to reduced physical ac-
tivity [19], which can also contribute to worsened dis-
ease outcomes. The association between depression and
anxiety and the subjective DAS28 elements would sug-
gest that depression/anxiety impact perceptions and be-
haviours, rather than immune dysregulation. Further
examination of mediators in this relationship is war-
ranted and potential targets for investigation are nega-
tive cognitions, behavioural activity and health
behaviours.
Increased levels of tenderness and poor patient global
assessments, despite well-managed inflammation, can in-
flate DAS28 scores thereby reducing the perceived effi-
cacy of treatment [28]. There is substantial evidence to
suggest that depression and anxiety can be effectively
treated in physical conditions [33, 34]. Given the import-
ance of the DAS28 in clinical decision making, the rou-
tine detection and management of depression and
anxiety may be a further strategy to improve disease
management [8], and doing so would align with National
Institute of Health and Clinical Excellence guidelines
[35].
Limitations
This study has some limitations to consider. Firstly, the
sample size is small, limiting statistical power and the
scope to control for pertinent covariates. Our selectivity
about covariates, whilst evidence-based, may have influ-
enced results, and inclusion of several other variables
such as comorbidities and ethnicity would have been
preferable. Future research would benefit from recruiting
patients with a clinician-verified RA diagnosis, rather
than relying on self-reported diagnosis. We have shown
that only 51.4 % of patients with a self-reported RA
diagnosis in fact, have clinically verified RA. A further
consideration was the lack of sociodemographic data
available; low socioeconomic status (SES) patients are
typically under-represented in research samples [36]. As
low SES is associated with increased susceptibility to de-
pression [37] and RA [38], our findings may not be
generalizable to the general RA population, although it
is important to note that KCH caters mostly for patients
in South East London, which has a higher level of
deprivation than the England average [39, 40]. Addition-
ally, we were unable to invite patients who could not
read/write English to complete the questionnaires, which
may further limit the generalisability of our findings to
the wider, non-English-speaking population.
Additionally, no information was collected during re-
cruitment about patients who declined to participate.
Therefore we were unable to determine participation rate,
examine any demographic, physical, or psychological
Table 3 Multiple regression model of unstandardized (b) coefficients for primary and secondary outcomes, measured 1-year
follow-up, by depression/anxiety severity at baseline
Primary
outcome
Secondary
outcomes
DAS28 ESR SJC TJC PGA
b(SE) 95 % CI p b(SE) 95 % CI p b(SE) 95 % CI p b(SE) 95 % CI p b(SE) 95 % CI p
Unadjusted
Depression 0.06
(0.02)
0.10,0.45 0.01 0.01
(0.04)
−0.06,0.09 0.74 0.12
(0.13)
−0.14,0.38 0.35 0.55
(0.22)
0.11,0.99 0.02 2.68
(0.80)
1.07,4.28 <0.01
Anxiety 0.04
(0.02)
−0.00,0.07 0.05 0.02
(0.03)
−0.05,0.08 0.63 0.06
(0.11)
−0.16,0.29 0.57 0.34
(0.20)
−0.06,0.75 0.09 2.30
(0.72)
0.85,3.75 <0.01
Adjusteda
Depression 0.03 (0.02) −0.00,0.06 0.07 0.01
(0.02)
−0.03,0.05 0.69 0.19
(0.13)
−0.07,0.45 0.16 0.59
(0.23)
0.13,1.05 0.01 2.07
(0.80)
0.46,3.69 0.01
Anxiety 0.02 (0.01) −0.00,0.05 0.06 0.02
(0.02)
−0.02,0.05 0.37 0.15
(0.11)
−0.07,0.38 0.18 0.44
(0.20)
0.04,0.85 0.03 2.13
(0.65)
0.81,3.45 <0.01
DAS28 28-joint disease activity score, ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint count, PGA patient global assessment
aModel adjusted for age, disease duration and baseline physical health for each variable (e.g. DAS28 at baseline adjusted for in DAS28 outcome assessment; ESR
at baseline adjusted for in ESR outcome assessment; etc.)
Bold text denotes significant association
Table 4 Logistic regression model of association between
depression and anxiety and odds of reaching clinical remission
at 1-year follow-up
DAS28 remission
OR (SE) 95 % CI p
Unadjusted
Depression −0.15 (0.11) −0.37,0.07 0.18
Anxiety −0.04 (0.08) −0.20,0.12 0.63
Adjusted
Depression −0.14 (0.17) −0.48,0.19 −0.48
Anxiety −0.01 (0.14) −0.28,0.26 0.94
OR odds ratio, SE standard error, CI confidence interval
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determinants of non-participation, or examine between-
group differences in patients who consented to participate
and those who did not. Future replication of this study
should attempt to record details for all patients
approached for recruitment.
A final limitation is the lack of data available regarding
medication usage throughout the follow-up period, for
either RA or mental disorder. DAS28 outcomes may be
substantially driven by treatment intensity and modality,
and treatment decision-making may be influenced by
patient mental-state [41]. The addition of medication
data may add valuable information to the understanding
of these relationships. Furthermore, the inclusion of
DAS28 data at only one follow-up point means that any
variation in disease activity throughout the follow-up
period, or as a result of treatment, cannot be assessed.
Future research may also benefit from taking into ac-
count change in depression and anxiety. There is some
prospective evidence suggesting initial depression levels
predict between 37 and 58 % of the variance in follow-
up mood scores in RA [42]. With a larger sample size, it
would be interesting to stratify our results by change in
mood over time, to see if the relationship between mood
and disease activity alters by mood trajectory.
Conclusions
This study supports the findings from previous research
indicating an association between depression and anxiety
scores at baseline and worsened disease outcomes [23,
25]. These findings have several implications. Inflated
DAS28 in the context of clinically well controlled disease
may indicate significant psychological morbidity rather
than true disease activity. Regardless of direction of
causality, the consistent association between depression
and anxiety and disease variables is strong, and depres-
sion and anxiety may act as easily identifiable and man-
ageable “psycho-markers” of adverse disease outcome
[43]. We recommend that depression and anxiety be
measured in routine clinical practice and as part of ran-
domised controlled trials for new treatments in RA.
Finally, research is required to determine whether ef-
fective treatment of depression and anxiety can improve
rheumatological outcomes. Psychological interventions
have been used to successfully improve disease out-
comes in diabetes and coronary heart disease [44], and
our results highlight the need to test a similar approach
in rheumatoid arthritis.
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